EP3292213A1 - Biomarker für den nachweis von aspirinunempfindlichkeit - Google Patents
Biomarker für den nachweis von aspirinunempfindlichkeitInfo
- Publication number
- EP3292213A1 EP3292213A1 EP16720828.9A EP16720828A EP3292213A1 EP 3292213 A1 EP3292213 A1 EP 3292213A1 EP 16720828 A EP16720828 A EP 16720828A EP 3292213 A1 EP3292213 A1 EP 3292213A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mir
- mirna
- inhibitor
- aspirin
- thromboxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims description 85
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 85
- 238000001514 detection method Methods 0.000 title description 7
- 239000000090 biomarker Substances 0.000 title description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 239000003112 inhibitor Substances 0.000 claims abstract description 30
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims abstract description 26
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims abstract description 22
- 108091047499 miR-1271 stem-loop Proteins 0.000 claims abstract description 18
- 108091091281 miR-1537 stem-loop Proteins 0.000 claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 230000035945 sensitivity Effects 0.000 claims abstract description 3
- 108091070501 miRNA Proteins 0.000 claims description 141
- 239000002679 microRNA Substances 0.000 claims description 141
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 20
- 229960000905 indomethacin Drugs 0.000 claims description 10
- 108091026495 miR-148b stem-loop Proteins 0.000 claims description 9
- 108091072763 miR-151 stem-loop Proteins 0.000 claims description 9
- 108091062221 miR-18a stem-loop Proteins 0.000 claims description 9
- 108091039812 miR-28 stem-loop Proteins 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 8
- 108091047189 miR-29c stem-loop Proteins 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 108091091696 miR-331 stem-loop Proteins 0.000 claims description 7
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 108091041042 miR-18 stem-loop Proteins 0.000 claims description 5
- 108091038080 miR-18a-1 stem-loop Proteins 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 3
- 238000011897 real-time detection Methods 0.000 claims description 2
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 66
- 239000000523 sample Substances 0.000 description 46
- 238000002493 microarray Methods 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 14
- 238000010606 normalization Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 210000004623 platelet-rich plasma Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 9
- 108091030146 MiRBase Proteins 0.000 description 9
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 108091089762 miR-1225 stem-loop Proteins 0.000 description 9
- 108091068733 miR-548e stem-loop Proteins 0.000 description 9
- 108091052481 miR-587 stem-loop Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- -1 miR-1280 Proteins 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- 108010029625 T-Box Domain Protein 2 Proteins 0.000 description 4
- 102100038721 T-box transcription factor TBX2 Human genes 0.000 description 4
- 102000003938 Thromboxane Receptors Human genes 0.000 description 4
- 108090000300 Thromboxane Receptors Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007211 cardiovascular event Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 238000010989 Bland-Altman Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108091062150 Homo sapiens miR-1271 stem-loop Proteins 0.000 description 2
- 108091051956 Homo sapiens miR-1537 stem-loop Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000025870 aspirin resistance Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108091030503 miR-1260 stem-loop Proteins 0.000 description 2
- 108091046552 miR-1260a stem-loop Proteins 0.000 description 2
- 108091028466 miR-130b stem-loop Proteins 0.000 description 2
- 108091026034 miR-130b-1 stem-loop Proteins 0.000 description 2
- 108091025972 miR-130b-2 stem-loop Proteins 0.000 description 2
- 108091079151 miR-29c-1 stem-loop Proteins 0.000 description 2
- 108091055145 miR-342 stem-loop Proteins 0.000 description 2
- 108091080700 miR-484 stem-loop Proteins 0.000 description 2
- 108091072577 miR-718 stem-loop Proteins 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 229940103114 simvastatin 40 mg Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102100026515 Cytochrome P450 2S1 Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000004150 Flap endonucleases Human genes 0.000 description 1
- 108090000652 Flap endonucleases Proteins 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108091044921 Homo sapiens miR-1225 stem-loop Proteins 0.000 description 1
- 108091044800 Homo sapiens miR-548e stem-loop Proteins 0.000 description 1
- 108091063776 Homo sapiens miR-587 stem-loop Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229950005722 flosulide Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 1
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical class CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000013450 outlier detection Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention relates to the field of diagnostics.
- the invention relates to a method for determining whether a patient is insensitive to a treatment with aspirin for use in a platelet inhibition treatment.
- anti-platelet and “platelet inhibiting” shall mean any inhibition of platelet activation and/or platelet aggregation and/or platelet adhesion.
- Platelet activation, aggregation and/or adhesion are believed to play significant roles in the pathogenesis of many vaso-occlusive disorders such as unstable angina, acute myocardial infarction, reocclusion of vessels following balloon angioplasty, transient ischemic attacks and strokes.
- vaso-occlusive disorders such as unstable angina, acute myocardial infarction, reocclusion of vessels following balloon angioplasty, transient ischemic attacks and strokes.
- chemical agonists bind with certain binding sites on circulating platelets, causing the platelets to become activated.
- the types of blood vessel wall damage that can trigger platelet activation include perforation or injury to the vessel wall, progression of atherosclerotic plaque, the performance of some interventional procedure (e.g., angioplasty, atherectomy or stenting), which stretches the vessel wall or causes intimal tearing, or other causes.
- platelets When activated, platelets interact with fibrinogen, fibronectin and other clotting factors causing them to adhere to the affected blood vessel wall and to aggregate with one another and with other blood cells (e.g., leukocytes). This activation, adherence and aggregation of platelets leads to the formation of a thrombus or blood clot.
- Aspirin is the most commonly prescribed platelet inhibitor for secondary prevention after a cardiovascular event, but other thromboxane A2 inhibitors or a selective COX-1 inhibitors could also be used. It is known that long-term treatment with aspirin significantly reduces the risk of myocardial infarction (Ml), stroke and vascular death. However, 10 to 20% of treated patients develop recurrent vascular events. A relatively high incidence of recurrent events is due to insensitivity to aspirin treatment. Indeed, it is known that there are large inter-individual differences in aspirin response and in some individuals platelet function is not decreased by aspirin treatment.
- kits for diagnosing or monitoring insensitivity treatment with a thromboxane A2 inhibitor or a selective COX-1 inhibitor, in particular of aspirin are provided, and to use said miRNA levels in the diagnosis of insensitivity to treatment with a thromboxane A2 inhibitor or a selective COX-1 inhibitor.
- the invention is based on the surprising finding that in healthy individuals, lower expression of miR- 19b-l-5p after aspirin use is associated with the insensitivity of platelets for aspirin.
- the inventors demonstrated that in vivo miRNA expression in isolated platelets, and in particular the expression of miR-19b-l-5p, shows a heterogeneous response to medication use in healthy individuals.
- the inventors showed that lower miR-19b-l-5p expression after aspirin use is associated with platelet insensitivity to indomethacin in vitro.
- Other objects of the present invention are to provide a kit for diagnosing or monitoring insensitivity of a patient for the treatment with thromboxane A2 inhibitor or a selective COX-1 inhibitor based upon the miRNA levels according to the invention, and to use said miRNA levels in the diagnosis of insensitivity to treatment with thromboxane A2 inhibitor or a selective COX-1 inhibitor.
- the invention provides a method for determining whether a patient is insensitive to a treatment with a thromboxane A2 inhibitor or a selective COX-1 inhibitor for use in a platelet inhibition treatment comprising the steps of determining the expression level of one or more miRNA(s) selected from the group consisting of miR-19b-l-5p, miR-1271, and miR-1537-5p, in a sample comprising platelet derived nucleic acids; comparing said expression level with a reference level, and determining the aspirin insensitivity of said subject based on the information obtained in the previous step.
- upregulation of said miRNA is indicative for insensitivity to treatment with a a thromboxane A2 inhibitor or a selective COX-1 inhibitor.
- upregulation of said miRNA is indicative for insensitivity to treatment with said thromboxane A2 inhibitor or said selective COX-1 inhibitor.
- said thromboxane A2 inhibitor or a selective COX-1 inhibitor is selected from the group consisting of aspirin and indomethacin.
- the method according to the invention comprises the step of determining the expression level of said miRNA in a sample before, during and/or after treatment with said thromboxane A2 inhibitor or said selective COX-1 inhibitor.
- the method of the invention comprises the step of determining the expression level of said miRNA in a sample after at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 , 13 or 14 days after the first doses of said thromboxane A2 inhibitor or said selective COX-1 inhibitor treatment.
- said one or more miRNA(s) comprises miR-19b-l-5p.
- said sample comprises a platelet sample.
- said expression level of said miRNA is normalized using one or more reference miRNAs.
- said one or more reference miRNAs is selected from the group consisting of consisting of miR-151-3p, miR-28-5p, miR-331-3p, miR-29c, miR-148b-3p and miR-18a.
- the detecting said one or more miRNA(s) is performed by reverse amplification of said miRNA and real time detection of amplified products.
- the invention further provides a kit for diagnosing or monitoring aspirin insensitivity comprising a nucleic acid capable of hybridizing under stringent conditions with miR-19b-l-5p, miR-1271, and miR- 1537-5p.
- said kit further comprises one or more reference miRNAs selected from the group consisting of miR-151-3p, miR-28-5p, miR-331-3p, miR-29c, miR-148b-3p and miR-18a.
- Figure 1 shows the inter-individual heterogeneity of medication-induced changes in miRNA microarray expression.
- Figure 2 shows the correlation between the in vivo changes in miRNA expression after aspirin use and in vitro platelet aggregation after indomethacin incubation. Correlation between the change in A) miR-19b-l-5p expression, B) miR-1537-5p expression and C) miR-1271 expression (log fold change of normalised RT-PCR expression after and before medication use) and the sensitivity of the platelets to aspirin as measured by the reduction in platelet aggregation.
- Figure 3 shows that the percentage of serum TXB2 reduction after two weeks of aspirin therapy varied among individuals.
- the article “a” and “an” as used herein refers to one or to more than one (i.e., at least one) of the grammatical object of the article.
- an element means one element or more than one element.
- Thiboxane inhibitors include compounds that inhibit thromboxane synthase and compounds that inhibit, prevent or otherwise interfere with the binding of thromboxane to its receptor
- Thromboxane synthase inhibitors and thromboxane receptor antagonists can be identified using assays described in Tai, H.-H. Assay of thromboxane A synthase inhibitors. Methods in Enzymology Vol 86, 1982 pp. 110-113 and references contained within Hall, S. E. Thromboxane A2 Receptor Antagonists. Medicinal Research Reviews, 11, 503-579 (1991) and Coleman, R. A., Smith, W. L, Narumiya, S.
- the characteristics of the preferred thromboxane inhibitor should include suppression of thromboxane A2 formation (thromboxane synthase inhibitors) and/or blockade of thromboxane A2 and prostaglandin H2 on platelets and vessel wall (thromboxane receptor antagonists). The effects should block platelet activation and therefore platelet function. Thromboxane synthase inhibitors may also increase the synthesis of antiaggregatory prostaglandins including prostacyclin and prostaglandin D2.
- a second class is the tricyclic inhibitor class, which can be further divided into the sub-classes of tricyclic inhibitors with a central carbocyclic ring (examples include SC-57666, 1, and 2); those with a central monocyclic heterocyclic ring (examples include DuP 697, SC-58125, SC-58635, and 3, 4 and 5; and those with a central bicyclic heterocyclic ring (examples include 6, 7, 8, 9 and 10).
- Compounds 3, 4 and 5 are described in U.S. Patent No. 5,474,995.
- the third identified class can be referred to as those which are structurally modified NSAIDs, and includes 11a and structure 11 as example members.
- ASA aspirin
- ortho-acetylsalicylic acid and the pharmaceutically acceptable formulations thereof.
- aspirin insensitivity or "aspirin resistance” refers to an inability to effectively inhibit the biosynthesis of thromboxane A2 after taking a thromboxane A2 inhibitor or a selective COX-1 inhibitor, most preferably aspirin by standard antiplatelet doses of 75-300 mg/day. It is believed that as a result thereof, aspirin loses its protective effect on cardiovascular and cerebrovascular system. In the majority of patients, aspirin can reduce the risk of cardiovascular and cerebrovascular diseases by 25%. However, for patients with aspirin resistance, treatment of cardiovascular and cerebrovascular diseases with aspirin cannot prevent them from the cardiovascular and cerebrovascular events, but instead, can increase the risk of myocardial infarction and stroke.
- determining the level of a certain mi NAs in a sample means assaying a test sample, e.g. a platelet sample from a patient, in vitro to determine the concentration or amount of the miRNAs in the sample. Any convenient qualitative, semi-quantitative or, preferably, quantitative detection method for determining nucleic acids can be used to determine the concentration or amount of the miRNAs in the sample. A variety of methods for determining nucleic acids are well known to those of skill in the art, e.g. determination by nucleic acid hybridization and/or nucleic acid amplification. Exemplary methods to determine the concentration or amount of the miRNAs in the sample are provided below.
- sample comprising platelet derived nucleic acids refers to any type of biological sample from a patient which comprises platelet derived nucleic acids, preferably RNA, in a detectable amount.
- miRNAs are small non-coding RNAs (17-24 nucleotides) that regulate gene expression by binding to partly complementary sequences in messenger RNA transcripts (mRNAs) thereby preventing the mRNAs from being translated into protein. Due to their function as regulators of gene expression they play a critical role in fundamental biological processes, including hematopoietic differentiation, cell cycle regulation, metabolism, cardiovascular biology, and immune function, and have been suggested to be involved in pathological processes. It has been found that the expression level (or expression pattern) of miRNAs varies over time and between tissues/cells.
- miR-19b-l-5p, miR-1271, miR-1537-5p, miR-1280, miR-1260a, miR-718, miR-484, MiR- 130b-3p, miR-342-3p miR-151-3p, miR-28-5p, miR-331-3p, miR-29c-3p, miR-148b-3p, miR-18a-5p refer to the miRNAs as retrieved in miRBase version 21. Exemplary sequences of the miRNAs are listed in Table 1.
- miR-1271 CUUGGCACCUAGCAAGCACUCA
- miR-151-3p CUAGACUGAAGCUCCUUGAGG
- miR-331-3p GCCCCUGGGCCUAUCCUAGAA
- miR-29c UAGCACCAUUUGAAAUCGGUUA
- miR-1225-3p UGAGCCCCUGUGCCGCCCCCAG 16.
- miR-587 UUUCCAUAGGUGAUGAGUCAC
- miR-718 CUUCCGCCCCGCCGGGCGUCG
- miR-484 UCAGGCUCAGUCCCCUCCCGAU
- miR-342-3p UCUCACACAGAAAUCGCACCCGU
- RNA may be extracted from the sample prior to miRNA processing for detection.
- RNA may be purified using a variety of standard procedures as described, for example, in RNA Methodologies, A laboratory guide for isolation and characterization, 2nd edition; 1998, Robert E. Farrell, Jr., Ed., Academic Press.
- miRNeasyTM kit Qiagen
- MagMAXTM kit Life Technologies
- Pure LinkTM kit Life Technologies
- mirVANATM miRNA Isolation Kit Ambion
- small molecular weight RNAs may be isolated by organic extraction followed by purification on a glass fiber filter.
- Alternative methods for isolating miRNAs include hybridization to magnetic beads.
- the determination of aspirin insensitivity is based on comparing the expression level(s) of the miRNAs in the patient's sample with those obtained using relevant controls, e.g. internal standards, samples of purified platelets from subjects known to be sensitive to aspirin treatment.
- relevant controls e.g. internal standards, samples of purified platelets from subjects known to be sensitive to aspirin treatment.
- the "control" may be test results obtained from the same patient at an earlier time, i.e., the patient may be examined for changes in microRNA levels before and after aspirin treatment.
- control i.e., control
- miRNAs or of miRNA ratios
- the step of determining whether a subject is sensitive or insensitive to aspirin treatment is based on the information obtained by comparison between the expression level with a reference level.
- the expression level(s) of the analysed miRNA(s) when statistically analysed will have a threshold whereby expression levels of the individual miRNAs below or above the threshold are indicative for respectively the presence or absence of aspirin insensitivity.
- Threshold miRNA levels for each of the analysed miRNAs can be determined by any suitable algorithm. Such an algorithm may involve classifying a sample between aspirin insensitive and aspirin sensitive groups.
- samples may be classified on the basis of threshold values, or based upon Mean and/or Median miRNA levels in aspirin insensitive patients versus aspirin sensitive (e.g., a cohort from the general population or a patient cohort with diseases unrelated to aspirin insensitivity).
- Mean and/or Median miRNA levels in aspirin insensitive patients versus aspirin sensitive (e.g., a cohort from the general population or a patient cohort with diseases unrelated to aspirin insensitivity).
- Various classification schemes are known for classifying samples between two or more groups, including Decision Trees, Logistic Regression, Principal Components Analysis, Naive Bayes model, Support Vector Machine model, and Nearest Neighbour model.
- the predictions from multiple models can be combined to generate an overall prediction.
- the miRNA expression level (miRNA signature, level, or miRNA concentration) is generated.
- RNA capture is determined from (in) the biological-sample using any of various methods known in the art for quantifying miRNA levels.
- methods include polymerase-based assays, such as Real-Time PCR (e.g., TaqmanTM), hybridization-based assays, for example using microarrays (e.g. miRNome microRNA Profilers QuantiMir Human PCR array (Biocat)), nucleic acid sequence based amplification (NASBA), flap endonuclease-based assays, as well as direct RNA capture with branched DNA
- polymerase-based assays such as Real-Time PCR (e.g., TaqmanTM)
- hybridization-based assays for example using microarrays (e.g. miRNome microRNA Profilers QuantiMir Human PCR array (Biocat)), nucleic acid sequence based amplification (NASBA), flap endonuclease-based assays, as well as direct RNA capture with branched DNA
- the assay format in addition to determining the miRNA levels will also allow for the control of, inter alia, intrinsic signal intensity variation.
- Such controls may include, for example, controls for background signal intensity and/or sample processing, and/or hybridization efficiency, as well as other desirable controls for quantifying miRNA levels across samples (e.g., collectively referred to as "controls").
- controls Many of the assay formats for amplifying and quantitating miRNA sequences, and thus for generating miRNA levels are commercially available and/or have been described, e.g. in WO 2008/153692, WO 2010/139810, and WO 2011/163214, or references cited therein.
- the specific platelet-based miRNAs that are tested for in the present invention include hsa-miR-19b- l-5p (miRBAse, version 21), hsa-miR-1225-3p (miRBAse, version 21), hsa-miR-1271 (miRBAse, version 21), hsa-miR-1537-5p (miRBAse, version 21), hsa-miR-548e-3p (miRBAse, version 21), and hsa-miR- 587 (miRBAse, version 21).
- the designations provided are standard in the art and are associated with specific sequences that can be found at the microRNA registry (http://www.mirbase.org/).
- hsa Homo sapiens
- hsa-miR-19b-l-5p hsa-miR-1271
- hsa-miR-1537- 5p under the standard nomenclature system.
- miRNAs tested for are indicated as RNA sequences, it will be understood that, when referring to hybridizations or other assays,
- RNA sequences may be reverse transcribed and amplified using the polymerase chain reaction (PCR) in order to facilitate detection. In these cases, it will actually be DNA and not RNA that is directly quantitated. It will also be understood that the complement of the reverse transcribed DNA sequences can be analysed instead of the sequence itself.
- the term "complement” refers to an oligonucleotide that has an exactly complementary sequence, i.e. for each adenine there is a thymine, etc.
- assays may be performed for the miRNAs individually, it is generally preferable to assay several miRNAs or to compare the ratio of two or more of the miRNAs.
- the method of the invention can comprise differentiating between patients with aspirin insensitivity and patients who are sensitive to aspirin treatment, wherein any of the miRNAs of the invention up- regulated (increased concentration) in the biological sample from a patient compared to a normal control.
- the method of the invention can further comprise determining the expression level of hsa-miR-19b-l-5p in the sample from the patient.
- Said sample may be any sample from said patient comprising platelet RNA. Examples include for instance, platelet rich plasma, whole blood,
- said sample is a sample of isolated platelets or enriched for platelets.
- said sample comprises a high concentration of platelets, preferably more than 99% of all cell particles in said sample is a platelet, preferably more than 99.5%, 99.6% or 99.7% as determined by FACS analysis.
- the method of the invention can further comprise determining the level of one or more normalization control(s) in the sample.
- the sample can be spiked with the normalization control(s).
- the normalization control can be a non-endogenous RNA or miRNA, or a miRNA not expressed in the sample.
- the normalization control may be one or more exogenously added RNA(s) or miRNA(s) that are not naturally present in the biological sample, e.g. an RNA or miRNA from another organism, and/or one or more human miRNAs not expressed in the sample-sample undergoing analysis.
- said level of the miRNA of the invention is normalized using one or more reference miRNAs which are stably expressed in platelets.
- said one or more reference miRNAs is selected from the group consisting of miR-151-3p, miR-28-5p, miR-331-3p, miR-29c, miR-148b-3p and miR-18a-5p.
- the normalization may suitably be performed as described herein and as described in European patent application EP15166257.
- the invention further provides a kit for quantifying the amount of a target miRNA in a biological sample comprising an amplification primer set, comprising at least one primer comprising a sequence that is complementary to a portion of said first reference miRNA as defined above.
- said amplification primer set further comprises a sequence that is complementary to a portion of said second reference miRNA as defined above.
- the kit of the invention further comprises a second amplification primer set, wherein at least one primer comprises a sequence that is complementary to a portion of a target miRNA.
- the kit according to the invention further comprises a first probe comprising a sequence that is complementary to a portion of the target miRNA and a second probe comprising a sequence that is complementary to a portion of the reference miRNA, wherein the first and second probes are distinguishably detectable.
- the miRNA level (or miRNA concentration) is preferably determined by an amplification-and/or hybridization-based assay.
- the amplification- and/or hybridization-based assay can be quantitative miRNA real-time polymerase chain reaction (RT-PCR), e.g. TaqMan.
- RT-PCR quantitative miRNA real-time polymerase chain reaction
- the miRNA level may also be determined by preparing cDNA, followed by RT-PCR.
- the miRNA level may be determined with the use of a custom kit or array, e.g., to allow particularly for the profiling of the platelet-based miRNAs of the invention. Accordingly, the present invention further provides a kit (or test) for diagnosing or monitoring insensitivity for aspirin treatment based upon the miRNA levels in the biological samples as described herein.
- the kit for diagnosing or monitoring aspirin insensitivity of the invention may comprise means for determining the concentration (expression level) of miR-19b-l-5p, miR-1225-3p, miR-1271, miR- 1537-5p, miR-548e-3p, and miR-587; in a platelet sample from a subject.
- the means for determining the concentration of miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537-5p, miR-548e-3p, and miR- 587 can be oligonucleotide probes specific for miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537-5p, miR-548e-3p, and miR-587; or miRNA-specific primers for reverse transcribing or amplifying each of miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537-5p, miR-548e-3p, and miR-587.
- the means for determining the concentration of miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537-5p, miR-548e-3p, and miR-587 may be TaqMan probes specific for each miRNA of the kit.
- oligonucleotide probes specific for miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537- 5p, miR-548e-3p, and miR-587; or miRNA-specific primers for reverse transcribing or amplifying each of miR-19b-l-5p, miR-1225-3p, miR-1271, miR-1537-5p, miR-548e-3p, and miR-587 to detect their expression levels (concentrations) in accordance with suitable assay formats is well known to those of skill in the art, and appropriate probes and/or primers can be commercially purchased.
- the kit may comprise an enzyme for cDNA preparation (e.g. , reverse transcriptase) and/or PCR amplification (e.g., Taq polymerase), and/or a reagent for detecting and/or quantifying miRNA. Additionally, the kit may further comprise include a reagent for miRNA isolation from samples.
- the kit can also comprise one or more normalization control(s). The normalization control(s) can, for example, be provided as one or more separate reagent(s) for spiking samples or reactions.
- the normalization control(s) is/are selected from non-endogenous RNA or miRNA, or a miRNA not expressed in the sample.
- said kit comprises a specific primer for reverse transcribing or amplifying one or more reference miRNAs is selected from the group consisting of miR-151-3p, miR-28-5p, miR-148b-3p and miR-18a.
- aspirin is the most commonly prescribed platelet inhibitor after a cardiovascular event. Many patients, however, suffer from re-events that are thought to be due to platelet insensitivity to aspirin. The aim of this study was to identify a biomarker which could be used as a suitable marker for aspirin insensitivity.
- Microarray cohort For the miRNA microarray experiments the inventors recruited 15 healthy Caucasian male volunteers. This group was part of a previously reported study (Sondermeijer BM et al. , PLoS One [Internet]. 2011 [cited 2013 Aug 12];6:e25946.), in which healthy controls were matched to patients with coronary artery disease (CAD). The original cohort consisted of 40 healthy controls, of which 24 individuals completed the medication regimen described below. Of these, 15 individuals additionally completed the platelet aggregation assays and were therefore included in the microarray cohort. Healthy volunteers were eligible for participation if they were between the age of 35 and 65 years, did not have a personal or family history of cardiovascular disease (CVD) and did not use any medication.
- CVD cardiovascular disease
- the inventors administered 100 mg of acetyl salicylic acid, once daily, for two weeks. Since this cohort was intended as a control group for a group of subjects with CAD, all subjects were also asked to use statins.
- the inventors administered simvastatin 40 mg, once daily, for 6 weeks, of which the last 2 weeks in combination with the administration of acetyl salicylic acid. Blood samples including isolated platelets were collected at baseline in the absence of aspirin and statins and after six weeks of medication use.
- the PC cohort consisted of the 15 healthy volunteers from the microarray cohort and 10 additional healthy volunteers. Additional participants were selected in a similar manner to the controls in the microarray cohort, using identical inclusion and exclusion criteria. The subjects were also treated with simvastatin 40 mg, once daily, for 6 weeks, of which the last 2 weeks in
- Venous blood samples were drawn without stasis, using an open system with a 19-gauge needle.
- Blood samples for platelet isolation were collected in trisodium citrate (each 5 ml containing 0.5 ml 0.105M trisodium citrate). The first sample was discarded.
- Blood samples for platelet aggregation test were collected in citrate tubes.
- Samples for the serum thromboxane A2 assay were collected in glass serum tubes.
- Platelets were isolated as described previously (Sondermeijer BM et al. , PLoS One [Internet]. 2011 [cited 2013 Aug 12];6:e25946.). In short, immediately after withdrawal the samples were centrifuged (180g, 15 min, room temperature) to obtain platelet-rich plasma (PRP). The upper layer of PRP was transferred to a plastic tube to avoid leukocyte contamination. One part of acid-citrate-dextrose (ACD) buffer (0.085 M trisodium citrate, 0.11 M glucose, 0.071 M citric acid) was added to five parts of PRP and then the PRP was centrifuged (800 g, 20 min, room temperature).
- ACD acid-citrate-dextrose
- the platelet-poor plasma was discarded and the platelet pellet carefully resuspended in Tyrode buffer (136.9 mM NaCI, 2.61 mM KCI, 11.9 mM NaHC03, 5.55 mM Glucose, 2 mM EDTA, pH 6.5).
- the platelet suspension was centrifuged (800 g, 20 min, room temperature). The supernatant was discarded and the platelet pellet was resuspended in 50 ml sterile phosphate buffered saline (PBS) and stored at -80 Q C prior to RNA isolation.
- the isolated platelets were investigated by fluorescence-activated cell sorting (FACS) using monoclonal antibodies against CD45 (BD Biosciences), CD235a (DAKO) and CD61 (BD
- RNA isolation The inventors isolated platelet RNA using the mirVana PARIS kit (Ambion, Inc.), according to the manufacturer's protocol for liquid samples. The protocol was modified such that samples were extracted twice with an equal volume of acid-phenol chloroform.
- RNA 6000 Pico kit Agilent Technologies
- Small RNA kit Agilent Technologies
- RNA including microRNAs 100 ng of total RNA including microRNAs was dried down in a Centrivap concentrator (Labconco) and dissolved in 2 ⁇ RNase-free water.
- Sample labeling with Cy3 was performed as described in the miRNA Microarray System with miRNA Complete Labeling and Hyb Kit manual version 2.2 (Agilent Technologies) with the inclusion of spike-ins and the optional desalting step with spin columns (Micro Bio-Spin 6, Bio-Rad). Labeled samples were hybridized on Human 8x15k miRNA microarrays based on Sanger miRBase release 12.0 containing 866 human and 89 human viral miRNAs (G4470C, Agilent Technologies) at 55°C and 20 rpm for 20 hours.
- the arrays were scanned using the Agilent DNA microarray scanner (G2565CA, Agilent Technologies). Data was extracted with Feature Extraction software (vlO.7.3.1, Agilent Technologies) with the miRNA_107_Sep09 protocol for miRNA microarrays miRNA microarray pre-processing and analysis
- qPCR was performed with RNA of isolated platelets as previously described (Tijsen AJ et al., Ore Res [Internet]. 2010 [cited 2013 Jun 24];106:1035-9). A fixed volume of 8 ⁇ of total RNA was used as input in the reverse transcription reaction. Input RNA was reverse transcribed using the miScript reverse transcription kit (Qiagen) according to the manufacturer's protocol. The real-time qPCR was performed using High Resolution Melting Master (Roche). MgCI 2 was used in final concentration of 2.5mmol/L and 2 ⁇ of 8 times diluted cDNA was used in a total volume of 10 ⁇ . The forward primers had the same sequence as the mature miRNA sequence with all U's changed into T's.
- the reverse sequence was GAATCGAGCACCAGTTACGC (SEQ ID NO:21), which is complementary to the adapter sequence of the RT-primer used to create cDNA.
- qPCR reactions were performed on a LightCycler480 system II (Roche).
- the candidate miRNAs were normalized to the geometric mean of a previously established miRNA normalization panel for platelet samples consisting of miR-151-3p, miR-28-5p, miR-148b-3p and miR-18a. These normalization miRNAs were selected from independent microarray experiments and were further validated on PCR data using the geNorm and Normfinder algorithms.
- the original platelet normalization panel consists of 6 miRNAs selected by both algorithms.
- ADP Adenosine diphosphate
- Serum thromboxane B2 (TXB2) was measured at baseline and after 2 weeks aspirin use to check compliance to the therapy.
- TXB2 was measured in duplicate by an enzyme-linked immunosorbent assay (R&D Systems) according to the manufacturer's instructions. The inventors calculated the TBX2 concentration by performing a logistic four-parameter fit of the standard concentrations versus the ratio of absorbance of a particular sample to that of the maximum binding sample.
- Microarray cohort Clinical characteristics of the 15 healthy volunteers included in the microarray cohort are reported in Table 1. The results of the serum TBX2 assay showed that all subjects complied to aspirin therapy.
- PCR cohort This cohort consisted of the 15 subjects of the microarray cohort and 10 additional healthy volunteers recruited in the same manner as the controls in the microarray cohort (Table 1). Clinical characteristics of these 10 healthy volunteers did not differ from those of the microarray cohort. Detailed characteristics of the PCR cohort are listed in Table 1. Also for these 10 healthy volunteers, compliance to aspirin therapy was good, as shown by the serum TBX2 assay.
- the miRNA microarray experiment was performed on platelet RNA samples obtained at baseline and after 6 weeks medication use for all 15 subjects included in the microarray cohort. Each microarray contained 866 human miRNAs as annotated in miRBase 12.0. In total 468 miRNAs were detected in at least one platelet sample.
- Medication- induced changes in expression of each miRNA on the microarray were correlated with the reduction in platelet aggregation after incubation with indomethacin. Changes in expression of six miRNAs correlated strongly with the extent of platelet aggregation reduction (Table 2)
- the inventors were able to perform RT- qPCR on 3 out of 6 candidate miRNAs (miR-1271, miR- 1537-5p and miR-19b-l-5p).
- the expression levels of the other 3 miRNAs were below the detection limit of their PCR system.
- Diastolic blood pressure mmHg ⁇ SD 84 ⁇ 8 84 ⁇ 7
- Triglycerides mmol/L ⁇ SD 1.0 ⁇ 0.5 1.2 ⁇ 0.7
- Continuous data are expressed as mean ⁇ SD, categorical data as absolute number with
- BMI body mass index
- HDL high density lipoprotein
- LDL low density lipoprotein
- n number
- SD standard deviation
- serum TXB2 levels were analysed in samples taken at baseline and after two weeks of aspirin therapy. At these time points the samples for the miRNA expression analyses were also taken. The percentage of serum TXB2 reduction after two weeks of aspirin therapy varied among individuals, but all participants had at least a 30% reduction, indicating good compliance of all individuals.
- Non-fasting venous blood was drawn in CTAD citrate 5,4 ml tubes (Becton Dickinson, Alphen aan de Rijn, the Netherlands) and centrifuged for 10 minutes at 158 g at 20°C without brake to obtain platelet rich plasma (PRP).
- CTAD citrate 5,4 ml tubes Becton Dickinson, Alphen aan de Rijn, the Netherlands
- PRP platelet rich plasma
- MiR-19b-l-5p specific reverse transcription was performed on lOOng of purified total RNA, using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Gent, Belgium). RT-qPCR reactions were carried out in duplicate, on a LightCycler 480 system II (Roche, Basel,
- Table 3 NO values (expression) of miR-19b-l-5p in PRP samples per sample.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15166277 | 2015-05-04 | ||
PCT/EP2016/059991 WO2016177776A1 (en) | 2015-05-04 | 2016-05-04 | Biomarkers for the detection of aspirin insensitivity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3292213A1 true EP3292213A1 (de) | 2018-03-14 |
Family
ID=53054891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16720828.9A Withdrawn EP3292213A1 (de) | 2015-05-04 | 2016-05-04 | Biomarker für den nachweis von aspirinunempfindlichkeit |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3292213A1 (de) |
WO (1) | WO2016177776A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110433170B (zh) * | 2019-07-31 | 2021-04-27 | 南京医科大学 | 心脏抽吸液miR-28-5p在心脏疾病中的应用 |
EP4118219A4 (de) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Neuartige verwendung von aspirinverbindung zum erhöhen der nukleinsäureexpression |
WO2024076307A1 (en) * | 2022-10-04 | 2024-04-11 | MiRXES Lab Pte. Ltd. | Compositions and methods for assessing nucleic acids in a biological sample |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
WO1994015932A1 (en) | 1993-01-15 | 1994-07-21 | G.D. Searle & Co. | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
AU6718494A (en) | 1993-05-13 | 1994-12-12 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
NZ536355A (en) | 1993-11-30 | 2006-08-31 | Searle & Co | Method of treating inflammation using substituted pyrazolyl benzenesulfonamides |
US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
AU5276696A (en) | 1995-04-04 | 1996-10-23 | Glaxo Group Limited | Imidazo{1,2-a}pyridine derivatives |
US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
JP3337477B2 (ja) | 1995-10-30 | 2002-10-21 | メルク フロスト カナダ アンド カンパニー | Cox−2阻害剤のプロドラッグとしての3,4−ジアリール−2−ヒドロキシ−2,5−ジヒドロフラン |
WO2008153692A2 (en) | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
EP2336353A1 (de) | 2009-12-17 | 2011-06-22 | febit holding GmbH | miRNA-Fingerabdrücke bei der Diagnose von Krankheiten |
US20120015830A1 (en) | 2010-06-21 | 2012-01-19 | Diogenix, Inc. | Microrna profiles for evaluating multiple sclerosis |
CA2818174A1 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions |
-
2016
- 2016-05-04 EP EP16720828.9A patent/EP3292213A1/de not_active Withdrawn
- 2016-05-04 WO PCT/EP2016/059991 patent/WO2016177776A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016177776A1 (en) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220033905A1 (en) | Method for diagnosis and prognosis of chronic heart failure | |
CA3029912A1 (en) | Biomarkers for inflammatory bowel disease | |
US9290813B2 (en) | Biomarkers for determining an allograft tolerant phenotype | |
TW200844238A (en) | HLA alleles associated with adverse drug reactions and methods for detecting such | |
US20150064704A1 (en) | Complex sets of mirnas as non-invasive biomarkers for early diagnosis of acute myocardial infarction | |
WO2014136870A1 (ja) | Rna修飾の簡易検出法、及び該検出法を用いた2型糖尿病の検査方法 | |
JP2013524809A (ja) | 心血管疾患のリスクを決定するための手段および方法 | |
WO2015183601A1 (en) | Predictive analysis for myocardial infarction | |
Schirmer et al. | Suppression of inflammatory signaling in monocytes from patients with coronary artery disease | |
EP3292213A1 (de) | Biomarker für den nachweis von aspirinunempfindlichkeit | |
Lynch et al. | Serum levels of miR-199a-5p correlates with blood pressure in premature cardiovascular disease patients homozygous for the MTHFR 677C> T polymorphism | |
US9617606B2 (en) | Oligonucleotide for HIV detection, HIV detection kit, and HIV detection method | |
US11525161B2 (en) | Methods of distinguishing ischemic stroke from intracerebral hemorrhage | |
EP2895625B1 (de) | Mit dasatinib-empfindlichkeit assoziierte gene | |
JP6974182B2 (ja) | 健康のサイン | |
JP2004113094A (ja) | 高血圧のリスク診断方法 | |
US20200024667A1 (en) | Mirna based treatment monitoring in multiple sclerosis | |
WO2017068198A1 (en) | Biomarker for predicting coronary artery disease in smokers | |
EP2603604A1 (de) | Verfahren und kit zur diagnose und/oder prognose der toleranz bei lebertransplantationen | |
US11479817B2 (en) | Methods for discriminating a tolerant subject | |
Kłoda et al. | hTERT, BICD1 and chromosome 18 polymorphisms associated with telomere length affect kidney allograft function after transplantation | |
JP6871271B2 (ja) | Dlbclを分類するための方法および組成物 | |
Tandarto et al. | miR-155 EXPRESSION UTILIZATION AS A POTENTIAL DIAGNOSTIC BIOMARKER OF HEART FAILURE: A SYSTEMATIC REVIEW: Received 2023-01-03; Accepted 2023-02-09; Published 2023-03-09 | |
CN105969895A (zh) | 一种使用逆转录pcr检测hla-b*5801基因表达的检测方法及试剂盒 | |
US20160194712A1 (en) | Mirna based treatment monitoring in autoimmune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20171204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180626 |